Article Listing - Protalix and Pfizer expand Elelyso agreement
Ranbaxy 1st-qtr 2013 earnings plunge 90% as sales fall 34%
8 May 2013
India's largest pharma company Ranbaxy Laboratories (BSE: 500359), which is majority owned by Japan's Daiichi Sankyo, has posted first quarter 2013 financial results, showing the net income plunged 90% to 1.26 billion rupees ($23.4 million), while sales fell 34.2% to 24.40 billion rupees compared with the 2012 first quarter, when the company benefited from sales exclusivity in the USA for a generic version for a generic version of Pfizer's all-time blockbuster Lipitor (atorvastatin).
Clinical success rates for new cancer drugs doubled from the mid-1990s to early-2000s, says Tufts CSDD
8 May 2013
Clinical success rates for new cancer drugs doubled between the mid-1990s to the early 2000s, while the number of new cancer drugs entering clinical testing increased 50 percent during the same time, according to an analysis recently completed by the Tufts Center for the Study of Drug Development.
ADHD drug development is "problematic;" drug repositioning trumps research
8 May 2013
While high disease prevalence is encouraging pharmaceuticals companies to enter into the attention-deficit hyperactivity disorder (ADHD) market, a lack of understanding surrounding the condition is making drug development problematic, states GBI Research in a new report focusing on the disease market.
Arena and Eisai finally get DEA scheduling for obesity drug Belviq
8 May 2013
The long wait to get obesity drug Belviq (lorcaserin) to the US market, where it was approved by the Food and Drug Administration nearly a year ago, is coming to a close, but not just yet. While finally getting a feedback from the US Drug Enforcement Administration, the effective date of the scheduling designation will be 30 days after today's (May 8) expected publication in the Federal Register.
Drais Pharma to develop third Astellas compound through Tacurion
8 May 2013
Japanese drug major Astellas Pharma (TYO: 4503) and USA-based Drais Pharmaceuticals have entered into a third partnership in the space of around a year to develop and commercialize an Astellas compound.
Eisai files for new Halaven indication; gets orphan status for lenvatinib in EU
8 May 2013
Japanese drug major Eisai (TYO: 4523) has filed a Type II Variation application with the European Medicines Agency for Halaven (eribulin), requesting an indication extension to include treatment of earlier line metastatic breast cancer (MBC) patients.
Diabetes drugs market forecast to reach $55.3 billion in 2017, with further growth to 2023
8 May 2013
A new report by Visiongain predicts the world market for diabetes medications will reach $55.3bn in 2017. The antidiabetic medicines industry generated $35.6 billion in 2012, and its revenues will show strong growth to 2023. That sales forecast and others appear in Diabetes Treatments: World Drug Market 2013-2023.
Australia to review way chemotherapy is funded
7 May 2013
Australia's Minister for Health Tanya Plibersek has announced a major review into the way chemotherapy is funded and provided as a way of ensuring the nation's cancer patients have continued access to quality, affordable treatment.
Positive results from sub-analysis of Eliquis ARISTOTLE trial
7 May 2013
US drug major Bristol-Myers Squibb (NYSE: BMY) and partner Pfizer (NYSE: PFE) reported results from a pre-specified sub-analysis of the ARISTOTLE trial (n=18,201) showing that the reduction in stroke or systemic embolism, number of major bleeding events and mortality demonstrated with Eliquis (apixaban) compared to warfarin were consistent across subgroups defined based on levels of International Normalized Ratio control in patients with non-valvular atrial fibrillation.
Alliance Boots to build up interest in China
7 May 2013
According to the Financial Times, Stefano Pessina, executive chairman of Alliance Boots, is looking to China for his next big deal, nine months after completing the multibillion pound sale of a stake in the retailer and pharmaceutical wholesaler to the USA's Walgreens, which initially took a 45% stake for $6.7 billion, with an option to buy the remainder (The Pharma Letter June 20, 2012).
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
